CDT CDT Equity Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1896212 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-70.5%
TTM EPS YoY199.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-49.2%
ROA-41.4%
ROIC (approx.)-37.1%
Asset turnover—
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio0.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $563,000 | $302,000 | $778,000 | $746,000 | $1.53M | $1.86M | $916,000 | $132,000 |
| SG&A expense | $3.33M | $2.70M | $2.88M | $20.41M | $5.50M | $3.09M | $2.70M | $3.38M |
| Operating income | -$3.90M | -$3.00M | -$3.66M | -$21.16M | -$7.03M | -$4.95M | -$3.62M | -$3.51M |
| Interest expense | — | — | — | $0 | $100,000 | $100,000 | $100,000 | -$97,000 |
| Net income | -$4.58M | -$4.64M | -$4.06M | -$21.32M | -$7.12M | -$6.03M | -$4.75M | -$2.41M |
| EPS (basic) | -288.89 | -8.71 | -5.56 | — | -1,779,500.00 | -10,940.11 | -3,670.27 | — |
| EPS (diluted) | -288.89 | -8.71 | -5.56 | — | -1,779,500.00 | -10,940.11 | -3,670.27 | — |
| Weighted avg. shares (diluted) | 15,864 | 532,999 | 730,461 | — | 4 | 551 | 1,295 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.72M | $747,000 | $97,000 | $1.51M | $3.84M | $3.33M | $2.13M | $554,000 |
| Short-term investments | — | — | — | — | — | — | $600,000 | $600,000 |
| Current assets | $4.39M | $2.94M | $3.05M | $4.38M | $7.09M | $6.39M | $5.95M | $2.71M |
| PP&E, net | $102,000 | $158,000 | $213,000 | $269,000 | $325,000 | $381,000 | $434,000 | $40,000 |
| Intangibles | — | — | — | — | — | — | $400,000 | — |
| Total assets | $158.73M | $126.71M | $127.09M | $5.65M | $8.55M | $7.99M | $7.71M | $4.19M |
| Current liabilities | $22.15M | $23.35M | $21.64M | $12.82M | $4.26M | $4.41M | $4.55M | $10.74M |
| Total liabilities | $22.33M | $23.61M | $21.64M | $12.82M | $4.27M | $4.46M | $4.63M | $10.99M |
| Shareholders' equity | $136.39M | $103.09M | $105.45M | -$7.17M | $4.28M | $3.53M | $3.08M | -$6.79M |
| Shares outstanding | 73,866 | 631,080 | 4.72M | 18 | 1.28M | 2.39M | 9.51M | 461 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.88M | -$544,000 | -$1.89M | -$4.64M | -$4.41M | -$2.18M | -$3.93M | -$3.81M |
| Capital expenditure | — | — | — | — | -$7,000 | $401,000 | $404,000 | $0 |
| Free cash flow | — | — | — | — | -$4.40M | -$2.58M | -$4.33M | -$3.81M |
| Investing cash flow | — | — | — | $595,000 | -$998,000 | -$401,000 | -$404,000 | $85,000 |
| Financing cash flow | $4.00M | $1.19M | $487,000 | $1.74M | $6.00M | $3.76M | $5.93M | $4.21M |
| Stock-based compensation | $199,000 | $200,000 | $198,000 | $211,000 | $1.58M | $160,000 | $234,000 | $362,000 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.